These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37966726)

  • 1. Targeted delivery of LXR-agonists to atherosclerotic lesions mediated by polydiacetylene micelles.
    Jamgotchian L; Devel L; Thai R; Poupel L; Huby T; Gautier E; Le Goff W; Lesnik P; Gravel E; Doris E
    Nanoscale; 2023 Nov; 15(46):18864-18870. PubMed ID: 37966726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.
    Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA
    Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver X receptor: a potential target in the treatment of atherosclerosis.
    Savla SR; Prabhavalkar KS; Bhatt LK
    Expert Opin Ther Targets; 2022 Jul; 26(7):645-658. PubMed ID: 36003057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of notch enhances the anti-atherosclerotic effects of LXR agonists while reducing fatty liver development in ApoE-deficient mice.
    Hao Y; Wang X; Zhang F; Wang M; Wang Y; Wang H; Du Y; Wang T; Fu F; Gao Z; Zhang L
    Toxicol Appl Pharmacol; 2020 Nov; 406():115211. PubMed ID: 32853627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide Amphiphile Supramolecular Nanostructures as a Targeted Therapy for Atherosclerosis.
    Mansukhani NA; Peters EB; So MM; Albaghdadi MS; Wang Z; Karver MR; Clemons TD; Laux JP; Tsihlis ND; Stupp SI; Kibbe MR
    Macromol Biosci; 2019 Jun; 19(6):e1900066. PubMed ID: 31066494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
    Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
    Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.
    Fessler MB
    Pharmacol Ther; 2018 Jan; 181():1-12. PubMed ID: 28720427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
    Srivastava RA
    Atherosclerosis; 2011 Jan; 214(1):86-93. PubMed ID: 21093860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport.
    Yuan W; Yu B; Yu M; Kuai R; Morin EE; Wang H; Hu D; Zhang J; Moon JJ; Chen YE; Guo Y; Schwendeman A
    J Control Release; 2021 Jan; 329():361-371. PubMed ID: 33188828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design.
    Oosterveer MH; Grefhorst A; Groen AK; Kuipers F
    Prog Lipid Res; 2010 Oct; 49(4):343-52. PubMed ID: 20363253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.
    Peng D; Hiipakka RA; Dai Q; Guo J; Reardon CA; Getz GS; Liao S
    J Pharmacol Exp Ther; 2008 Nov; 327(2):332-42. PubMed ID: 18723776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-steroidal LXR agonists; an emerging therapeutic strategy for the treatment of atherosclerosis.
    Bennett DJ; Cooke AJ; Edwards AS
    Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):21-46. PubMed ID: 18221072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate.
    Lim RK; Yu S; Cheng B; Li S; Kim NJ; Cao Y; Chi V; Kim JY; Chatterjee AK; Schultz PG; Tremblay MS; Kazane SA
    Bioconjug Chem; 2015 Nov; 26(11):2216-22. PubMed ID: 25945727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver X receptor modulators: a review of recently patented compounds (2007 - 2009).
    Li X; Yeh V; Molteni V
    Expert Opin Ther Pat; 2010 Apr; 20(4):535-62. PubMed ID: 20302451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of tissue selective liver X receptor agonists for the treatment of atherosclerosis without causing hepatic lipogenesis.
    Li C; Chen H; Chen X; Li Y; Hua P; Wei J; Song C; Gu Q; Zhou H; Zhang J; Xu J
    Eur J Med Chem; 2019 Nov; 182():111647. PubMed ID: 31499362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes.
    Briley-Saebo KC; Shaw PX; Mulder WJ; Choi SH; Vucic E; Aguinaldo JG; Witztum JL; Fuster V; Tsimikas S; Fayad ZA
    Circulation; 2008 Jun; 117(25):3206-15. PubMed ID: 18541740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological role of liver X receptors.
    Baranowski M
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 7():31-55. PubMed ID: 19258656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LXR agonists for the treatment of atherosclerosis.
    Jaye M
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1053-8. PubMed ID: 14582448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.